RESPECT: find out what it means to ADCs, says Eisai subsidiary

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Svisio
Image: iStock/Svisio

Related tags: Pre-clinical development, Marketing, Immune system

Morphotek Inc has launched an antibody-drug conjugate (ADC) services business incorporating its RESPECT site-specific conjugation technology and eribulin-linker toxin platform.

The firm – a US subsidiary of Tokyo, Japan-based pharma company Eisai Co Ltd – has several of its own monoclonal antibodies in preclinical and clinical development but will now be offering its conjugation and linker technologies to others looking to develop ADCs.

Morphotek’s proprietary ADC platform includes the REsidue-SPEcific Conjugation Technology (RESPECT) technology offering site-specific conjugation of cytotoxic payloads.

According to the firm, this platform offers high conjugation efficiency and is highly reproducible, but can also be used to attach two payloads with different mechanisms of action through the firm’s eribulin-linker technology.

Eribulin, an approved anticancer small molecule drug marketed by parent company Eisai as Halaven, has shown potent antitumor activity and good safety profile when used in conjugation with an antibody.

“Decades of expertise in antibody engineering and clinical development of biologics-based therapies, along with preclinical studies showing the potential of our new ADC formats, has enabled us to align these assets into a client-focused ADC business offering end-to-end services,”​ Morphotek CEO Nicholas Nicolaides said in a statement.

“We believe this new service provides an opportunity to build a win-win strategy by increasing internal value through leveraging our proprietary platforms and development know-how, and customer value by developing ADCs to their strategic targets.”

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more